Table 1.
Demographic Characteristics At Enrollment of Participants with MCSA Study Follow-up
| pRBD+ | pRBD− | Total | p value | |
|---|---|---|---|---|
| Subjects | 44 | 607 | 651 | |
| Age (years) | 78 (75, 82) | 77 (74, 82) | 77 (74, 82) | 0.36 |
| Male gender | 34 (77.3) | 421 (69.4) | 455 (69.9) | 0.27 |
| Education (years) | 12 (12, 16) | 14 (12, 16) | 14 (12, 16) | 0.38 |
| Charlson Index of Comorbid Disease | 2 (1, 4) | 2 (0, 3) | 2 (0, 4) | 0.13 |
| Parkinsonism | ||||
| UPDRS Motor Subtest – Total | 0 (0, 5) | 0 (0, 2) | 0 (0, 2) | 0.63 |
| Total ≥ 4 | 12 (27.3) | 111 (18.3) | 123 (18.9) | 0.16 |
| Total ≥ 10 | 2 (4.5) | 33 (5.4) | 35 (5.4) | 1.00 |
| Kokmen Short Test of Mental Status | 34 (33, 36) | 35 (33, 36) | 35 (33, 36) | 0.49 |
| Study Follow-up (months) | 46 (31, 47) | 46 (33, 48) | 46 (33, 48) | |
| Neurodegenerative Syndrome Evolved | 15 (34.1) | 94 (15.5) | 109 (16.7) | |
| MCI† | 14 (31.8) | 90 (14.8) | 104 (16.0) | |
| Dementia† | 0 (0.0) | 8 (1.3) | 8 (1.2) | |
| PD† | 1 (2.3) | 4 (0.7) | 5 (0.8) | |
| Age at onset of pRBD (years) | 69 (35, 76) | |||
|
Duration of pRBD [median; mean (25th, 75th percentile)] |
7.5; 18.7 (2.0, 41.5) | |||
| Use of antidepressant# | 10 (22.7) | 40 (6.6) | 50 (7.7) | 0.001 |
| pRBD temporally related to use | 2 (4.5) | |||
| OSA features | ||||
| Snorted/choked themselves awake | 20 (45.5) | 139 (22.9) | 159 (24.4) | 0.002 |
| Stopped breathing when asleep | 12 (27.3) | 92 (15.2) | 104 (16.0) | 0.052 |
Numbers in table are N (%) or Median (25th percentile, 75th percentile). Data at enrollment are presented, unless otherwise indicated. MCI: Mild Cognitive Impairment, MCSA: Mayo Clinic Study of Ageing, OSA: Obstructive Sleep Apnoea, PD: Parkinson’s Disease, pRBD: probable REM Sleep Behavior Disorder, UPDRS: Unified Parkinson’s Disease Rating Scale (Part III).
Subjects can be included in multiple categories: 2 pRBD- subjects developed PD then MCI, 6 pRBD- subjects developed MCI then dementia. 2 pRBD- subjects did not have MCI detected before dementia and are only counted as dementia.
Includes selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), and tri- and tetra-cyclic antidepressants. Data includes incident use.